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ABSTRACT
Objective: The objective of the present study was to prepare and evaluate a novel oral formulation of nanoparticles for the systemic delivery of low-
molecular-weight heparin (LMWH).
Methods: Nanoparticles were prepared by polyelectrolyte complexation method using polymers, i.e., sodium alginate and chitosan (CH). Fourier 
transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (XRD), entrapment efficiency, In vitro release and 
scanning electron microscopic studies were carried out for nanoparticles. Ex vivo permeation studies were performed with optimized formulation 
using small intestine of rat and in vivo studies were conducted on rat model.
Results: Entrapment efficiency of LMWH in nanoparticles was found to be 88%. In vitro release studies demonstrated that the release of LMWH was 
negligible in the stomach and high in the small intestine. FTIR has indicated that there is no interaction between the ingredients in nanoparticle. DSC 
and XRD studies confirmed that the amino groups of CH interacted with the carboxylic groups of alginate. In vitro % drug release of 95% was shown by 
formulation AC5. Ex vivo permeation studies have elucidated that ~73% of LMWH was transported across the epithelium. Nanoparticles have shown 
enhanced oral bioavailability of LMWH as revealed by 4.5-fold increase in area under the curve of plasma drug concentration-time curve.
Conclusion: The results suggest that the nanoparticles prepared can result in targeted delivery of LMWH into systemic circulation through intestinal 
and colon routes. Novel nanoparticles thus prepared in this study can be considered as a promising delivery system.
Keywords: Antifactor Xa activity, Chitosan, Differential scanning calorimetry, Sodium alginate, Low-molecular-weight heparin, Oral bioavailability.
INTRODUCTION
Low-molecular-weight heparin (LMWH) is used as an anticoagulant 
in mostly two common post-surgical complications such as deep 
vein thrombosis and pulmonary embolism. It is used for long-term 
dosing through parenteral route and hence has reduced patient 
compliance. This can be improved by administering LMWH through 
the oral route. However, its clinical application through oral route 
is limited because of its large molecular size, high negative charge, 
instability in gastrointestinal region, and high water solubility. 
However, several studies addressed oral delivery of LMWH into 
systemic circulation. Various approaches have been investigated 
such as microemulsions, nanoparticles, microparticles, pellets, and 
chemical conjugates [1-5]. Yet, no oral formulation is able to produce 
good oral bioavailability and is not available in the market yet now. 
Since LMWH is permeable in the lower small intestine and colon, 
its penetration enhancement can be conveniently used to produce 
a market viable oral formulation for LMWH. Subsequently, in the 
present study, attempts were made to prepare and evaluate LMWH 
nanoparticles.
Nanoparticles were selected as they have the following advantages 
(a) they offer protection against acidic environment and enzymatic 
degradation, (b) its small size and the bioadhesive polymers used 
help in prolonging the gastric transit and permeating the mucous 
membrane. Particle size (1000 nm) is considered as a crucial 
parameter for bioadhesion and adsorption through the mucosal 
membrane. Paracellular and endocytic pathway are the major 
transport mechanisms for the transport of nanoparticles which 
majorly depended on particle size [6]. Various types of nanoparticles 
have been studied earlier [7,8]. Polyelectrolyte complexation (PEC) 
method is selected for preparation of nanoparticles as these are 
considered as the emerging delivery systems for the oral delivery 
of proteins, nucleic acids [9,10], etc. A combination of chitosan (CH) 
and alginate was used as the polyelectrolyte combination. Previously 
studies indicated that such nanoparticles are gastric resistant. Further, 
the natural bioadhesive property of the combination can lead to more 
residence on the mucosal membrane which in turn can result in 
significant systemic LMWH.
PEC is formed by spontaneous interaction of oppositely charged 
polysaccharides in aqueous solution. Polysaccharides are of particular 
importance due to their desirable biocompatible, biodegradable, 
hydrophilic, and protective properties. PEC method has the advantage 
of not using sonication and organic solvents which are harmful for 
proteins and polysaccharides. Previous investigations confirmed 
that CH and alginate were widely used for PEC formation and they 
have profound applications in drug or gene delivery systems in 
biomedicine [11,12].
CH is a linear polysaccharide composed of randomly distributed 
β-(1-4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-
glucosamine (acetylated unit) [13]. It is a biocompatible, biodegradable 
polymer, having inherent mucoadhesive properties with the capacity to 
open tight junctions in the mucosal membrane. The positive charge of 
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CH forms a strong bond with the negatively charged epithelial lining of 
gastrointestinal tract. This high interaction helps in opening the tight 
junction and makes the drug to reach the systemic circulation. However, 
it is mostly soluble in acidic pH conditions of the stomach, which makes 
it to lose its mucoadhesive and permeation enhancing properties. To 
overcome this, in the present study, a complex was formed between 
CH and a natural polyanion to improve the physicochemical property 
of CH. One of the polyanionic polymers that are widely used is sodium 
alginate (SA).
SA is an anionic polysaccharide distributed widely in the cell walls of 
brown algae. It is a linear copolymer with homopolymeric blocks of 
(1-4)-linked β-D- mannuronate (M) and its C-5 epimer α-L-guluronate 
(G) residues, covalently linked together in different sequences or 
blocks. The negatively charged carboxylic acid groups of mannuronic 
and guluronic acid units of alginate interact electrostatically with 
positively charged amino groups of CH to form polyelectrolyte. At 
a pH of 2.5, SA is negatively charged. As the pH increases from 2.5, 
the number of anionic charges on the SA was increased. While at 
pH <6.5, CH is positively charged. The pH values, i.e. 4.0 for CH and 
6.5 for SA ensures an increased charge density on each polymer 
and leads to intense cross-linking on mixing [14]. SA is mostly used 
as polyelectrolyte that forms complex with CH because the complex 
formed between the polymers is still biodegradable, biocompatible, 
and mechanically stronger in acidic pH conditions where CH dissolves. 
A research work has demonstrated that CH alone was effectively 
degraded by lysozymes [15,16]. However, this enzyme effect on 
PEC is negligible because of the strong interaction between the two 
polymeric chains.
In this study, PEC is formed by one-stage process. In this method, one 
polymer solution of a particular pH is added dropwise to the other 
polymer solution of a certain pH under high shearing conditions. In the 
present work, LMWH loaded PEC nanoparticles were formulated and 
it’s in vitro release and in vivo absorption are compared with LMWH CH 




Enoxaparin sodium (LMWH) was purchased from Bharath Biotech, 
Hyderabad, India. CH, sodium tripolyphosphate (STPP), dialysis 
membrane (MW 12,000 Daltons), and cetyl pyridinium chloride were 
purchased from Sigma-Aldrich Private Limited, Mumbai, India. SA was 
purchased from SD Fine Chemicals Limited, Gujarat, India. Stachrom 
Heparin supplied by Diagnostica Stago, Asnieres-sur-Seine, France. All 
the other chemicals and reagents were of analytical grade and used 
as supplied. Simulated gastric fluid pH 1.2, simulated intestinal fluid 
of pH 6.8 and 7.4 were prepared by referring to official methods as 
specified in USP (XXV).
Methods
Reagents used for analysis
To 1 ml of standard solution, 1 ml of 1 M acetate buffer of pH 5 and 
4 ml of cetyl pyridinium chloride solution (0.1%) in sodium chloride 
(0.94%) were added and reacted for 1 hr. Samples were then analyzed 
at 500 nm in ultraviolet (UV)-visible spectrophotometer [17].
Preparation of PEC nanoparticles of alginate and CH
SA solution was prepared by dissolving SA in reverse osmosis (RO) 
water. CH solution was prepared by dissolving CH in 1% acetic acid 
solution. Both the solutions were placed separately on magnetic stirrer 
at 100 rpm for 1 hr. LMWH (20 mg) was then added to SA solution 
and dissolved. SA solution was adjusted to pH 6.5 and CH solution to 
pH 4.0. SA solution is then slowly added to CH solution at a flow rate 
of 1 ml/s with the help of high-speed homogenizer (Unidrive X1000D 
Homogenizer drive, CAT scientific laboratory, California) at 10,000 rpm. 
Alginate in CH PECs was thus formed [10].
Preparation of CH nanoparticles
Nanoparticles were prepared by ion gelation of CH with STPP aqueous 
solution. First, CH was dissolved in 1% solution of acetic acid. LMWH 
was then added to CH solution and mixed. Aqueous solution of STPP 
was added dropwise to CH solution by magnetic stirring at room 
temperature using high-speed homogenizer [18].
In vitro characterization of PEC nanoparticles
PEC nanoparticles and its formulation components were 
subjected to Fourier transform infrared (FTIR) (Bruker Alpha-E 
spectrophotometer, Ettlingen, Germany), differential scanning 
calorimetry (DSC) (automatic thermal analyzer, DSC 910S, TA 
Instruments, America), X-ray diffraction (XRD) (X’Pert-PRO 
multipurpose X-ray diffractometer, PANalytical, Tokyo, Japan), 
scanning electron microscopy (LEO 435 VP, Eindhoven Netherlands), 
and particle size and zeta potential studies (Zetasizer, Model 3000 
HSA, Malvern Instrument, WR14 1XZ, UK).
Entrapment efficiency (EE)
The EE of LMWH in PEC nanoparticles was performed by an 
indirect method. The amount of unentrapped LMWH in the 
nanoparticles suspension was analyzed by taking the supernatant 
after centrifugation at 15000 rpm for 20 minutes. Then, aliquots 
of 1 ml of the supernatant was taken and mixed with reagents as 
discussed previously in the methods and reacted for 1 hr. Later, the 
absorbance of these samples was taken at 500 nm using UV-visible 
spectrophotometer. The study was performed in triplicate, and the 
percentage EE was determined [19].
EE





The study was performed 1-3 hrs after the preparation of PECs. RO 
water was used as the blank and adjusted to 100% transmittance at 
800 nm using UV-visible spectrophotometer [10]. The % transmittance 
of PEC nanoparticles was then measured.
In vitro release study
The in vitro release study of LMWH from drug loaded PEC nanoparticles 
was performed using the dialysis membrane method. LMWH PEC 
nanoparticulate suspension was filled in a dialysis bag (MW-12,000 Da) 
which was attached to a two-end opened boiling tube [20]. The boiling 
tube was then dipped in a beaker containing 50 ml of pH 1.2 buffer 
and placed on a magnetic stirrer for 2 hrs at 37±0.5°C and 50 rpm. The 
medium was then replaced with pH 6.8 buffer and after 3 hrs with pH 7.4 
buffer. The release study was performed for 24 hrs. Aliquots of 0.5 ml 
were taken at regular intervals, i.e. 1, 2, 3, 4, 5, 6, 8, 10 up to 24 hrs and 
analyzed by using UV-visible spectrophotometer at 500 nm. The same 
experiment was performed for plain CH nanoparticles and analyzed.
The release data were then fitted to different kinetic models, and the 
best fit model was determined based on R2 values.
Ex vivo drug release study
The amount of LMWH transported across the intestinal barrier was 
measured. Small intestine of male Wistar rat was removed and rinsed 
with normal saline solution. LMWH loaded PEC nanoparticulate 
suspension was filled in the membrane, and both ends were tied with 
a thread separately and fixed to a stand. The membrane was then 
introduced into 50 ml of 6.8 pH buffer in a beaker. The beaker was 
then placed on a magnetic stirrer at 37°C and 100 rpm. Aliquots of 1 ml 
were taken at intervals of 5, 15, 30, 45, 60, 90, 120 minutes up to 8 hrs. 
The samples were then analyzed by UV-visible spectrophotometer at 
500 nm by the addition of reagents and reacted for 1 hr. Permeation 
studies were performed in triplicate [21].
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Stability studies
The LMWH loaded PEC nanoparticles were studied for stability studies 
at various temperatures such as 4±1°C and 25±1°C and examined 
at regular time intervals for any change in particle size and drug 
content [19].
Oral absorption studies in rats
All animal studies were approved by the Institutional Ethical 
Committee, Warangal, registered under CPCSEA, India (IAEC 
no. 1047/ac/07/CPCSEA). Male Wistar rats (weighting 130±20 g) 
were taken and fastened overnight with free access to water before 
the administration of formulations. Three groups of animals were 
taken, each group containing six animals. Group 1 is considered as 
control which was a plain LMWH solution (50 mg/kg) and given orally 
to rats. Formulations such as LMWH loaded plain CH nanoparticulate 
suspension and PEC nanoparticles were administered orally to Group 
2 and Group 3 rats, respectively, in the same dose. To Group 3, LMWH 
loaded PEC nanoparticles were administered orally in the same dose. 
Blood samples were withdrawn from the retro-orbital plexus at 0, 1, 
2, 3, 4, and 5 up to 8 hrs. LMWH was quantified using an anti-factor 
Xa chromogenic assay. Anti-factor Xa activity versus time profile of 
LMWH in the plasma was then plotted and compared with that of 
the oral LMWH solution. Plasma concentrations of the drug were 
estimated, and different pharmacokinetic parameters were evaluated. 
Clotting time studies were performed with a plain LMWH solution, 
LMWH CH nanoparticles, and LMWH PEC nanoparticles on Wistar 
rats using a laboratory method as specified in reference [22,23]. 
Briefly, formulations were administered to three groups of animals as 
mentioned above. At regular time intervals, i.e. 0, 1, 2, 3, 4 up to 8 hrs 
blood samples were collected and their clotting time was determined 
by capillary method.
RESULTS
PECs were frequently prepared by mixing two electrolyte solutions 
of opposite charges. Various quantities of alginate and CH were taken 
at desirable pH conditions and complexes were prepared (Table 1). 
The formation of PECs was confirmed by FTIR and DSC studies. 
From the FTIR spectrum of LMWH loaded PEC nanoparticles; it was 
observed that the asymmetric and symmetric carboxylate anion 
(COO−) stretching was shifted from 1661 to 1638/cm and from 1450 
to 1439/cm, respectively. Furthermore, the absorption band of CH was 
shifted from 1582 to 1546/cm and the broadening of band from 1510 
to 1400/cm was attributed to the overlapping of amide of CH with 
carboxyl anion of alginate (Table 2). No characteristic bands of LMWH 
were observed in the spectrum of nanoparticulate formulation (Fig. 1). 
DSC confirms the presence of interaction between CH and alginate. As 
observed from the thermograms shown in Fig. 2, the endotherms of 
CH and SA were exhibited at 111.63°C and 130°C which indicates the 
evaporation of absorbed water. An endotherm of PEC nanoparticles was 
observed at 99.6°C which is lower than the endothermic peaks of CH 
and SA individually. This indicates that the hydrophilic groups in the 
PECs were more exposed possibly due to the formation of gaps after 
complexation. Exothermic peaks registered in 320.54°C, 253.58°C, and 
281.4°C for CH, SA, and PEC nanoparticles, respectively, indicate that 
PEC nanoparticles have a peak value intermediate between the peaks 
of SA and CH.
This peak value was interpreted as an interaction between the two 
polymers [24]. XRD spectra of PEG nanoparticles have shown the 
presence of 2 peaks of SA and a large bump. This indicates that SA was 
exposed on the outer surface and concealed the CH groups. The large 
bump indicates the entrapment of drug and formation of PEC (Fig. 3).
Two types of nanoparticles were prepared, i.e., PEC nanoparticles and 
CH nanoparticles. CH nanoparticles were only used for comparison, in 
in vitro and in vivo studies. Morphology of the PEC nanoparticles was 
determined by scanning electron microscopy (SEM) study. The shape of 
the PEC nanoparticles was found to be almost spherical (Fig. 4).
From the Table 1, it was observed that most of the alginate (AG), CH PEC 
nanoparticles have good % entrapment efficiencies. With increase in 
concentration of CH, the EE was increased. This was because of the 
increased number of complexes that are formed between CH and AG. 
The formulation AC6 has shown higher % EE. One of the reasons behind 
this is the interaction of CH with AG, and the other was the interaction 
of CH with LMWH which was negatively charged leading to higher EE. 
For obtaining a qualitative measure of the size of PECs, percentage 
transmittance studies were performed for formulations AC3 to AC9 at 
800 nm. At this wavelength, both AG and CH do not absorb any light [10]. 
Decrease in % transmittance was a measure of increased particle size 
(Table 3). This may be because of the repulsion between the excess 
positive charges provided by the CH molecule in nanoparticles.
From the in vitro release studies, it was observed that <1% of drug 
was released within 2 hrs in pH 1.2 buffer (Fig. 5). The complex 
was tough enough in the stomach because of the insolubility of AG 
at the particular pH [25]. In pH 6.8 and pH 7.4 buffer, a constant 
release of the LMWH was observed with a maximum release of 
90% of the initial amount. CH nanoparticles have shown 31.45% 
release of the drug in 1.2 pH buffer, which was not seen in PEC 
nanoparticles. The results of release kinetics revealed that the mode 
of drug release from PEC nanoparticles followed the Higuchi model 
with r2>0.8654 (Table 4). Data were also fitted into the Korsmeyer–
Peppas equation to determine the drug release mechanism further. 
The n value indicates super case-II transport [26]. Formulation AC3 
was considered less stable as it has shown aggregation and increased 
particle size within 10 days. Taking into consideration EE, in vitro 
release the formulations AC4, AC5, AC7, and AC8 were evaluated 
for particle size, zeta potential, and polydispersity index (Table 5). 
Particle size was found to increase with increase in CH concentration. 
The zeta potential values have shown a shift in charge on the surface 
of nanoparticles from higher to lower negative values. Polydispersity 
Table 1:Composition and % EE of PEC nanoparticles
Formulation LMWH (mg) CH (mg) SA (mg) Acetic acid (%v/v) Water (ml) % EE
AC1 20 100 100 1 100 45.5±2.65%
AC2 20 200 100 1 100 50.5±2.73%
AC3 20 200 250 1 100 77.25±0.8%
AC4 20 300 150 1 100 72.26±1.1%
AC5 20 300 250 1 100 84.88±0.87%
AC6 20 300 400 1 100 88.15±0.9%
AC7 20 350 100 1 100 67.43±0.48%
AC8 20 350 200 1 100 80.86±0.63%
AC9 20 400 300 1 100 87.26±0.7%
AC10 20 500 100 1 100 Viscous fibrous preparation
AC11 20 500 200 1 100 Viscous fibrous preparation
AC12 20 500 300 1 100 Viscous fibrous preparation
Data are expressed as mean±SD (n=3). SD: Standard deviation, LMWH: Low molecular weight heparin, CH: Chitosan, SA: Sodium alginate, EE: Entrapment efficiency, 
PEC: Polyelectrolyte complexation
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index values <0.5 indicate that the formulation was homogeneous in 
nature.
In the results of ex vivo studies, 73% and 62% of the drug were found 
to cross the intestinal membrane for AC4 and AC5 formulations, 
respectively, and reach the buffer in 6 hrs time period (Fig. 6). The 
optimized nanoparticle formulation was subjected to stability studies 
at different storage temperatures in terms of particle size and EE. The 
nanoparticles showed better stability at 4°C than at 25°C in terms of 
increased particle size and decreased EE (Table 6).
Fig. 1: Schematic diagram showing Fourier transform infrared spectra’s of (a) Pure sodium alginate, (b) pure chitosan, (c) low-molecular-
weight heparin (LMWH), (d) polyelectrolyte complexed nanoparticles of LMWH
Fig. 2: Differential scanning calorimetry thermograms of (a) pure chitosan (CH), (b) pure sodium alginate, (c) polyelectrolyte complexed 
alginate/CH nanoparticles
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Fig. 3: X-ray diffraction patterns of polyelectrolyte complexation nanoparticles and its formulation ingredients
Table 2: Important band frequencies in FTIR spectrum of drug, 
pure polymer, and nanoparticle




1661 Asymmetric carboxylate anion (COO−) stretch
1450 Symmetric carboxylate anion (COO−) stretch
1252 C-O stretch
1145 Bridge-O-stretch
997 C-O-C stretch due to saccharide structure
Pure CH
3247 O-H stretch and N-H stretch
2928 C-H stretch
1652 Amide I NH CO stretch







1418 C-H stretch of methyl group
1217 C-O stretch
987




1638 Asymmetric carboxylate anion (COO−) tretch
1546 Amide II N-H bend
1439 Symmetric carboxylate anion (COO−) stretch
1152 Bridge-O-stretch
1002 C-O-C stretch
LMWH: Low molecular weight heparin, CH: Chitosan, SA: Sodium alginate, 
PEC: Polyelectrolyte complexation, FTIR: Fourier transform infrared
Fig. 4: Scanning electron microscopic micrographs of low-
molecular-weight heparin loaded polyelectrolyte complexation 
nanoparticles
Fig. 5: In vitro release profile of low molecular weight heparin 
loaded polyelectrolyte complexation nanoparticles in 
different pH environments. Data represent mean±satndard 
deviation (n=6)
Pharmacokinetic parameters were determined from the plasma 
concentration-time profile of different formulations (Table 7). 
For LMWH plain oral solution, the Cmax value was observed to be 
0.10±0.007 IU/ml after 2 hrs of oral administration, while administration 
of CH nanoparticles enhanced the Cmax to 0.16±0.02 IU/ml. However, 
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the maximum value was observed for LMWH loaded PEC nanoparticles, 
which was 0.45±0.03 IU/ml. Similarly, area under the curve0-8 h of LMWH 
was increased by 1.8 times for LMWH CH nanoparticles and 4.5 times 
for LMWH PEC nanoparticles when compared with a plain oral LMWH 
solution (Fig. 7). The results of clotting time studies have revealed an 
enhancement in clotting time (Fig. 8).
DISCUSSION
FTIR and DSC studies confirmed that the PEC was formed between AG 
and CH. DSC and XRD studies indicated that AG and CH were transformed 
to amorphous forms on complexation and LMWH was entrapped. 
SEM studies revealed that the formed nanoparticles were of spherical 
shape and the micrographs did not show the appearance of aggregated 
particles. Based on % EE and % transmittance studies, the formulations 
AC4, AC5, AC6, AC7, and AC8 were optimized. In vitro release studies 
indicate that PEC nanoparticles were successful in retarding the release 
of drug in acidic pH conditions and capable of releasing 90% of the drug 
in simulated intestinal fluid within 10 hrs time period. This release of 
LMWH in small intestine could be because of the interaction of AG with 
alkaline media and an increase in the solubility of AG [27].
The possible mechanism of drug release from LMWH PEC nanoparticles 
was found to be super case-II transport, which was considered as 
swelling-controlled release. It was observed that with an increase 
in concentration of CH the particle size was increased and the zeta 
potential value has shifted toward lower negative charges. The negative 
charge demonstrates that AG has formed complex with CH and helped 
in concealing CH from degradation in the gastric environment. Ex vivo 
permeation studies indicated that the enhanced transport of PEC 
nanoparticles was ascribed to the mucoadhesive property of CH and 
the size of nanoparticles [28].
One of the research articles demonstrated that LMWH loaded 
trimethyl CH nanoparticles have shown 2.4 times bioavailability of 
LMWH in comparison to plain LMWH solution [19]. Pharmacokinetic 
studies of the present study have shown an enhancement in oral 
bioavailability of LMWH by 4.5 times when compared with a plain 
LMWH solution. This enhanced oral bioavailability was attributed 
to the interaction of AG and CH, which prevented the degradation of 
drug in gastric fluid. PEC nanoparticles then enter the small intestine 
where the AG gets slowly dissolved exposing the amino groups 
of CH. These amino groups get attached to the negative charge of 
epithelial lining and help with paracellular transport across the 
intestinal epithelium. This results in delivery of the drug to systemic 
circulation without damaging the intestinal epithelium. The in vitro 
and in vivo evaluation of PEC nanoparticles demonstrates that the 
Table 3: Percentage transmittance study of alginate/CH formulations
Alginate/CH formulations AC3 AC4 AC5 AC6 AC7 AC8 AC9
Percentage transmittance 90±1.23% 94±2.6% 92±1.79% 84±3.21% 89±1.4% 90±2.9% 80±1.1%
Data are expressed as mean±SD (n=3). SD: Standard deviation, CH: Chitosan
Table 4: Comparison of estimated parameters deduced from in vitro LMWH release curve of PEC nanoparticles in mixed pH media by 
fitting to various kinetic models
Formulation Zero order First order Higuchi model Hixon- crowell Korsmeyer Peppas
r2 r2 r2 r2 r2 n
AC3 0.4821 0.5692 0.8774 0.1753 0.9917 1.21
AC4 0.3991 0.4054 0.8654 0.1759 0.9802 0.89
AC5 0.5537 0.8772 0.9112 0.2862 0.9935 1.07
AC7 0.6029 0.5524 0.9019 0.2862 0.9848 1.51
AC8 0.5833 0.7472 0.8965 0.1926 0.9903 1.32
Data are expressed as mean±SD (n=3). SD: Standard deviation, LMWH: Low-molecular-weight heparin, PEC: Polyelectrolyte complexation
Table 5: Particle size, zeta potential, and polydispersity index of 
LMWH loaded PEC nanoparticles
Formulation Particle size Zetapotential Polydispersity 
index
AC4 119±1.3 nm −22±0.6 0.25±0.02
AC5 142±0.8 nm −08±0.4 0.33±0.03
AC7 195±0.3 nm −24±0.8 0.41±0.01
AC8 253±2.5 nm −12±0.2 0.11±0.06
Data are expressed as mean±SD (n=3). SD: Standard deviation, 
LMWH: Low-molecular-weight heparin, PEC: Polyelectrolyte complexation
Fig. 6: Cumulative percent transport of low molecular weight 
heparin from polyelectrolyte complexation nanoparticles AC4 
and AC5. Data represent mean±standard deviation (n=6)
Fig. 7: Antifactor Xa activity profile of low-molecular-weight 
heparin (LMWH) oral solution, LMWH chitosan nanoparticles, 
and LMWH polyelectrolyte complexation nanoparticles after oral 
administration in equivalent dose of 50 mg/kg in Wistar rats. 
Data represent mean±standard deviation (n=6)
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nanoparticulate system can be considered as a useful oral delivery 
system for enhancing the bioavailability of LMWH.
CONCLUSION
The approach to the oral delivery of LMWH is of utmost importance to 
prevent the invasive delivery. CH nanoparticles can be considered for 
oral delivery, but the high solubility of CH in acidic pH conditions makes 
it less suitable for oral administration. Hence, PEC nanoparticles were 
developed with AG and CH to overcome the limitations associated with 
plain CH nanoparticles. The developed PEC nanoparticles have shown 
an enhanced oral bioavailability in comparison with a plain LMWH 
solution. The present investigation suggests that the AG complexed 
CH nanoparticles could be effectively explored for the oral delivery of 
LMWH.
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